Gabapentin Shortage: What Providers and Prescribers Need to Know in 2026

Gabapentin is among the most frequently prescribed drugs in the United States, with over 73 million prescriptions written in 2024. While no active FDA-declared shortage exists for standard oral forms as of early 2026, prescribers across primary care, neurology, psychiatry, and pain medicine continue to field patient calls about difficulty locating specific formulations. This brief provides a clinical overview of the current landscape for Gabapentin availability and evidence-based strategies for managing patients who cannot access their medication.

Current Supply Status: What Prescribers Need to Know

As of early 2026:

• Gabapentin immediate-release capsules and tablets (all strengths): No active FDA shortage. Multiple generic manufacturers (Amneal, Hikma, Lupin, Aurobindo, Teva, and others) produce IR formulations, providing robust supply redundancy.
• Gabapentin oral solution (250 mg/5 mL): Shortage declared by ASHP in May 2023 (Mylan/Viatris supply interruption). Resolved as of July 2024 with Acella and Amneal supplying the market. Monitor local availability for patients requiring liquid formulation — particularly pediatric patients and those with dysphagia.
• Gralise and Horizant (brand extended-release formulations): No shortage. These brands have narrower FDA indications and smaller patient populations — Gralise for PHN only; Horizant for RLS and PHN. Supply is less constrained.

Understanding Why Patients Report Access Issues

When patients call your office unable to fill their Gabapentin, several non-shortage factors are typically at play:

• High local demand outpacing pharmacy stock cycles: With 73M annual prescriptions, even minor local demand spikes can temporarily deplete individual pharmacy inventories.
• State-level Schedule V classification: In Kentucky, West Virginia, Tennessee, Alabama, Utah, and Virginia, Gabapentin is classified as Schedule V. Pharmacies in these states face additional tracking and dispensing requirements, which can affect how much they keep on hand and how frequently they reorder.
• Insurer restrictions and prior authorization for brand formulations: While generic IR Gabapentin is typically Tier 1 or 2 on most formularies, brand-name Horizant and Gralise often require prior authorization. Patients denied coverage may struggle with cost barriers rather than supply barriers.
• Mismatched strength availability: The 300 mg capsule is the most widely stocked form. Patients prescribed 400 mg capsules or 100 mg capsules may encounter local stock gaps more frequently.

Clinical Implications for Discontinuation Risk

Gabapentin discontinuation carries meaningful clinical risk that must be communicated clearly to patients who cannot access their medication:

• Seizure breakthrough: Abrupt cessation in patients using Gabapentin as adjunctive anticonvulsant therapy can provoke seizures. Even in patients who haven't had a seizure in years, sudden discontinuation creates risk.
• Withdrawal syndrome: Abrupt discontinuation can produce withdrawal symptoms including anxiety, insomnia, nausea, diaphoresis, and pain. Patients should be instructed to contact the office immediately rather than self-discontinue.
• Pain crisis: Patients using Gabapentin for PHN, diabetic neuropathy, or other chronic pain conditions may experience acute pain flare upon discontinuation, driving ED visits.

Prescribing Strategies When Patients Cannot Access Gabapentin

When a patient reports unavailability, consider the following clinical approaches:

1. Substitute with the most available IR strength. If 400 mg capsules are unavailable, prescribe 300 mg capsules with adjusted quantity. The 300 mg capsule is the most universally stocked form.
2. Bridge to Pregabalin if clinically appropriate. Pregabalin has higher bioavailability and equivalent or superior efficacy for many Gabapentin indications. Conversion is approximately 300 mg Gabapentin TID → 100 mg Pregabalin BID, though titration should be individualized. Note Pregabalin is Schedule V federally.
3. Authorize early refills or emergency supplies. Provide a written authorization for early dispensing. For patients in states with Schedule V status, documentation of medical necessity may be required.
4. Direct patients to pharmacy inventory tools. Recommending Medfinder (medfinder.com) or similar pharmacy inventory lookup tools reduces the burden on your office staff fielding "where can I get it?" calls and empowers patients to locate stock on their own.
5. Consider compounding pharmacies for liquid formulation needs. If a pediatric patient or adult patient requiring liquid Gabapentin cannot source the commercial oral solution, a licensed compounding pharmacy can prepare a suspension to specification.

Patient Communication Recommendations

Proactively communicate with patients on Gabapentin about the following:

• Do not stop Gabapentin abruptly — always contact the office first
• Try to refill prescriptions a few days before they run out
• Consider 90-day mail-order fills for long-term prescriptions
• For practices with high volumes of patients on Gabapentin, consider a provider account with Medfinder for providers to streamline pharmacy routing for your most affected patients